X0708 D LIVE 0001857044 Indaptus Therapeutics, Inc. 3 COLUMBUS CIRCLE NEW YORK NY NEW YORK 10019 (646) 427-2727 DELAWARE None Intec Parent Inc. Corporation true 2021 Jeffrey A. Meckler Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York NY NEW YORK 10019 Executive Officer Director Michael J Newman Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York NY NEW YORK 10019 Executive Officer Director Nir Sassi Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York NY NEW YORK 10019 Executive Officer Walt A. Linscott Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York NY NEW YORK 10019 Executive Officer Roger J. Waltzman Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York NY NEW YORK 10019 Executive Officer Roger J. Pomerantz Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York NY NEW YORK 10019 Director Hila Karah Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York NY NEW YORK 10019 Director Anthony J. Maddaluna Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York NY NEW YORK 10019 Director William B. Hayes Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York NY NEW YORK 10019 Director Mark J. Gilbert Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York NY NEW YORK 10019 Director Robert E. Martell Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York NY NEW YORK 10019 Director Pharmaceuticals Decline to Disclose 06c false 2025-06-12 false true true false 0 Paulson Investment Company, LLC 000005670 None None 10220 SW Greenburg Rd Suite 380 Portland OR OREGON 97223 CA CALIFORNIA CO COLORADO FL FLORIDA GA GEORGIA HI HAWAII ID IDAHO IL ILLINOIS KS KANSAS MD MARYLAND MA MASSACHUSETTS MI MICHIGAN MN MINNESOTA NV NEVADA NJ NEW JERSEY NY NEW YORK NC NORTH CAROLINA OK OKLAHOMA OR OREGON PA PENNSYLVANIA SC SOUTH CAROLINA TX TEXAS UT UTAH VA VIRGINIA WA WASHINGTON WI WISCONSIN true 5000000 2314800 2685200 Offering of convertible notes in the aggregate principal amount of up to $5 million, convertible into shares of common stock, together with warrants to purchase shares of common stock. Approximately $2.3 million raised as of initial closing date. false 20 600000 true 0 The Issuer paid the placement agent (i) 12% of gross proceeds in the offering, (ii) a $25,000 non-accountable expense and (iii) a number of warrants equal to 12% of the shares issuable upon conversion of the notes sold in the offering. 0 The Company intends to use the net proceeds from the Offering for research and development activities including the funding of a Phase 1b/2 clinical trial as well as for working capital and general corporate purposes. false Indaptus Therapeutics, Inc. /s/ Nir Sassi Nir Sassi Chief Financial Officer 2025-06-20